314 related articles for article (PubMed ID: 38288299)
1. Nuclear medicine imaging for bone metastases assessment: what else besides bone scintigraphy in the era of personalized medicine?
Ouvrard E; Kaseb A; Poterszman N; Porot C; Somme F; Imperiale A
Front Med (Lausanne); 2023; 10():1320574. PubMed ID: 38288299
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma?
Aryal A; Kumar VS; Shamim SA; Gamanagatti S; Khan SA
Clin Orthop Relat Res; 2021 Aug; 479(8):1768-1779. PubMed ID: 33635285
[TBL] [Abstract][Full Text] [Related]
4. Comparison of
Dadgar H; Norouzbeigi N; Jokar N; Zareizadeh J; Gholamrezanezhad A; Ahmadzadehfar H; Abbaszadeh M; Assadi M
World J Nucl Med; 2022 Mar; 21(1):1-8. PubMed ID: 35502272
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
6. [Superiority of 18F-FNa PET/CT for Detecting Bone Metastases in Comparison with Other Diagnostic Imaging Modalities].
Lapa P; Saraiva T; Silva R; Marques M; Costa G; Lima JP
Acta Med Port; 2017 Jan; 30(1):53-60. PubMed ID: 28501038
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases.
Iagaru A; Mittra E; Dick DW; Gambhir SS
Mol Imaging Biol; 2012 Apr; 14(2):252-9. PubMed ID: 21479710
[TBL] [Abstract][Full Text] [Related]
8. Which metabolic imaging, besides bone scan with 99mTc-phosphonates, for detecting and evaluating bone metastases in prostatic cancer patients? An open discussion.
Bombardieri E; Setti L; Kirienko M; Antunovic L; Guglielmo P; Ciocia G
Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):381-99. PubMed ID: 26337240
[TBL] [Abstract][Full Text] [Related]
9. The role of 18F-NaF PET/CT in metastatic bone disease.
Araz M; Aras G; Küçük ÖN
J Bone Oncol; 2015 Sep; 4(3):92-7. PubMed ID: 26587375
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Bone Metastases between
Wang D; Yang Y; Zeng Z; Ye J; Guo C; Huang S; Guo X; Xiao J
Contrast Media Mol Imaging; 2022; 2022():5975338. PubMed ID: 35494210
[TBL] [Abstract][Full Text] [Related]
11. Molecular imaging of bone metastases using tumor-targeted tracers.
Karamzade-Ziarati N; Manafi-Farid R; Ataeinia B; Langsteger W; Pirich C; Mottaghy FM; Beheshti M
Q J Nucl Med Mol Imaging; 2019 Jun; 63(2):136-149. PubMed ID: 31315347
[TBL] [Abstract][Full Text] [Related]
12.
Langsteger W; Rezaee A; Pirich C; Beheshti M
Semin Nucl Med; 2016 Nov; 46(6):491-501. PubMed ID: 27825429
[No Abstract] [Full Text] [Related]
13. Comparison of the diagnostic value of 18F-NaF PET/CT and
Fan Z; Wang T; Zou L; Liu D
Transl Cancer Res; 2023 Nov; 12(11):3166-3178. PubMed ID: 38130318
[TBL] [Abstract][Full Text] [Related]
14. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
Ak I; Sivrikoz MC; Entok E; Vardareli E
Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657
[TBL] [Abstract][Full Text] [Related]
15. A Prospective Study Comparing
Löfgren J; Mortensen J; Rasmussen SH; Madsen C; Loft A; Hansen AE; Oturai P; Jensen KE; Mørk ML; Reichkendler M; Højgaard L; Fischer BM
J Nucl Med; 2017 Nov; 58(11):1778-1785. PubMed ID: 28798033
[TBL] [Abstract][Full Text] [Related]
16. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
17. Bone metastases diagnosis possibilities in studies with the use of 18F-NaF and 18F-FDG.
Tarnawska-Pierścińska M; Hołody Ł; Braziewicz J; Królicki L
Nucl Med Rev Cent East Eur; 2011; 14(2):105-8. PubMed ID: 22219151
[TBL] [Abstract][Full Text] [Related]
18. Detection of the Prostate Cancer Bone Metastases: Is It Feasible to Compare 18F-fluorocholine PET/CT, 18F-fluorodeoxyglucose PET/CT and 99mTc-methyl Diphosphonate Bone Scintigraphy?
Pietrzak AK; Czepczynski R; Wierzchoslawska E; Cholewinski W
Urol J; 2018 Sep; 15(5):242-247. PubMed ID: 29681049
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
